NO20013397L - Anvendelse av apoptose-induserende midler ved behandling av (auto)immune sykdommer - Google Patents

Anvendelse av apoptose-induserende midler ved behandling av (auto)immune sykdommer

Info

Publication number
NO20013397L
NO20013397L NO20013397A NO20013397A NO20013397L NO 20013397 L NO20013397 L NO 20013397L NO 20013397 A NO20013397 A NO 20013397A NO 20013397 A NO20013397 A NO 20013397A NO 20013397 L NO20013397 L NO 20013397L
Authority
NO
Norway
Prior art keywords
auto
apoptosis
treatment
immune disorders
inducing agents
Prior art date
Application number
NO20013397A
Other languages
English (en)
Norwegian (no)
Other versions
NO20013397D0 (no
Inventor
Mathieu Hubertus Mari Noteborn
Alexandra Maria Pietersen
Original Assignee
Leadd Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadd Bv filed Critical Leadd Bv
Publication of NO20013397D0 publication Critical patent/NO20013397D0/no
Publication of NO20013397L publication Critical patent/NO20013397L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20013397A 1999-01-11 2001-07-09 Anvendelse av apoptose-induserende midler ved behandling av (auto)immune sykdommer NO20013397L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99200056 1999-01-11
PCT/NL2000/000013 WO2000041497A2 (en) 1999-01-11 2000-01-10 Use of apoptosis inducing agents in the treatment of (auto)immune diseases

Publications (2)

Publication Number Publication Date
NO20013397D0 NO20013397D0 (no) 2001-07-09
NO20013397L true NO20013397L (no) 2001-09-11

Family

ID=8239795

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013397A NO20013397L (no) 1999-01-11 2001-07-09 Anvendelse av apoptose-induserende midler ved behandling av (auto)immune sykdommer

Country Status (18)

Country Link
US (1) US20050271624A1 (de)
EP (1) EP1143994B1 (de)
JP (1) JP2003500336A (de)
AT (1) ATE244014T1 (de)
AU (1) AU3083500A (de)
CA (1) CA2359392A1 (de)
DE (1) DE60003632T2 (de)
DK (1) DK1143994T3 (de)
EA (1) EA200100770A1 (de)
ES (1) ES2202039T3 (de)
HU (1) HUP0200552A2 (de)
IL (2) IL144228A0 (de)
MX (1) MXPA01006998A (de)
NO (1) NO20013397L (de)
PT (1) PT1143994E (de)
TR (1) TR200102713T2 (de)
WO (1) WO2000041497A2 (de)
ZA (1) ZA200105632B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60229924D1 (de) * 2001-03-30 2009-01-02 Leadd Bv Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
DE60217326T2 (de) * 2001-05-25 2007-10-18 Nymox Corp., Saint-Laurent Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung
CA2453965C (en) * 2001-07-19 2016-01-19 Nymox Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5981502A (en) * 1990-09-12 1999-11-09 Leadd B.V. Methods and compositions for inducing apoptosis in tumor cells
EP0878546A1 (de) * 1997-04-15 1998-11-18 Leadd B.V. Genabgabe-Vehikel die das Apoptosis VP2 inducierendes Protein, und/oder Apoptin exprimiert
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
ATE241808T1 (de) * 1995-06-07 2003-06-15 Leadd Bv Verwendungen von apoptin
WO1997029201A2 (de) * 1996-02-07 1997-08-14 Max-Delbrück-Centrum für Molekulare Medizin Retroviraler vektor für den gentransfer eines il6-antagonisten in humane hämatopoetische stammzellen
AU729063C (en) * 1997-02-28 2005-02-03 Boehringer Ingelheim Pharmaceuticals, Inc. Self-regulated apoptosis of inflammatory cells by gene therapy
JPH10324699A (ja) * 1997-03-21 1998-12-08 Sankyo Co Ltd 抗ヒトＦａｓヒト化抗体
IL123756A0 (en) * 1997-03-21 1998-10-30 Sankyo Co Humanized anti-human FAS antibody

Also Published As

Publication number Publication date
IL144228A0 (en) 2002-05-23
CA2359392A1 (en) 2000-07-20
WO2000041497A2 (en) 2000-07-20
ATE244014T1 (de) 2003-07-15
EA200100770A1 (ru) 2002-02-28
DE60003632T2 (de) 2004-04-15
ES2202039T3 (es) 2004-04-01
JP2003500336A (ja) 2003-01-07
DE60003632D1 (de) 2003-08-07
EP1143994B1 (de) 2003-07-02
US20050271624A1 (en) 2005-12-08
DK1143994T3 (da) 2003-10-20
EP1143994A2 (de) 2001-10-17
PT1143994E (pt) 2003-11-28
ZA200105632B (en) 2002-10-09
IL144228A (en) 2009-06-15
TR200102713T2 (tr) 2002-05-21
WO2000041497A3 (en) 2000-09-28
HUP0200552A2 (en) 2002-06-29
NO20013397D0 (no) 2001-07-09
MXPA01006998A (es) 2002-05-06
AU3083500A (en) 2000-08-01

Similar Documents

Publication Publication Date Title
TNSN08064A1 (en) Albumin fusion proteins
AU2002258808A1 (en) Humanized antibodies
AU2002257162A1 (en) Humanized antibodies
NZ593905A (en) Il-1 binding proteins
WO2005077042A3 (en) Albumin fusion proteins
WO2003060071A3 (en) Albumin fusion proteins
MX2009002816A (es) Proteinas de fusion de albumina.
WO2001079443A3 (en) Albumin fusion proteins
HUP0300369A2 (hu) Többértékű antitestek és alkalmazásuk
ATE403680T1 (de) Herstellung tetravalenter antikörper
NZ502527A (en) Catalytic monoclonal antibodies raised to proteins in aggregated form, and use to treat alzheimers, atherosclerosis, amyloidosis and prions disease
FI963101A (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut
WO2007038637A3 (en) Human monoclonal antibodies to cd70
WO2001064889A3 (en) Tnf-alpha variants for the treatment of tnf-alpha related disorders
WO2002018620A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2003033658A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2001098491A3 (en) Osteolevin gene polymorphisms
WO1999028460A3 (en) Molecules interacting with apoptin
NO20013397L (no) Anvendelse av apoptose-induserende midler ved behandling av (auto)immune sykdommer
IL154298A0 (en) Papap proteins, their preparation and use
MXPA03000979A (es) Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas.
MXPA03010728A (es) Moleculas de proteina-2 relacionadas con b7 y uso de las mismas.
EP1161262A4 (de) AN DER OBERFLÄCHE VON KARZINOMZELLEN LOKALISIERTES COLLIGIN/HsP47
EP1475441A3 (de) Spezifische Nukleinsäuren und Polypeptide aus krankheitserregenden Stämmen von Neisseria
WO2002072632A3 (en) Nucleic acids of the human abcc11 gene, vectors containing such nucleic acids and uses thereof.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application